202 related articles for article (PubMed ID: 33116240)
41. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.
Rigolin GM; del Giudice I; Formigaro L; Saccenti E; Martinelli S; Cavallari M; Lista E; Tammiso E; Volta E; Lupini L; Bassi C; Bardi A; Sofritti O; Daghia G; Cavazzini F; Marinelli M; Tavolaro S; Guarini A; Negrini M; Foà R; Cuneo A
Genes Chromosomes Cancer; 2015 Dec; 54(12):818-26. PubMed ID: 26355802
[TBL] [Abstract][Full Text] [Related]
42. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
43. Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.
Wu SJ; Lin CT; Agathangelidis A; Lin LI; Kuo YY; Tien HF; Ghia P
Haematologica; 2017 Jun; 102(6):1085-1090. PubMed ID: 28255015
[TBL] [Abstract][Full Text] [Related]
44. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
45. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Lazarian G; Tausch E; Eclache V; Sebaa A; Bianchi V; Letestu R; Collon JF; Lefebvre V; Gardano L; Varin-Blank N; Soussi T; Stilgenbauer S; Cymbalista F; Baran-Marszak F
Int J Cancer; 2016 Oct; 139(8):1759-63. PubMed ID: 27270786
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
[TBL] [Abstract][Full Text] [Related]
47. 14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Cosson A; Chapiro E; Belhouachi N; Cung HA; Keren B; Damm F; Algrin C; Lefebvre C; Fert-Ferrer S; Luquet I; Gachard N; Mugneret F; Terre C; Collonge-Rame MA; Michaux L; Rafdord-Weiss I; Talmant P; Veronese L; Nadal N; Struski S; Barin C; Helias C; Lafage M; Lippert E; Auger N; Eclache V; Roos-Weil D; Leblond V; Settegrana C; Maloum K; Davi F; Merle-Beral H; Lesty C; Nguyen-Khac F;
Genes Chromosomes Cancer; 2014 Aug; 53(8):657-66. PubMed ID: 24729385
[TBL] [Abstract][Full Text] [Related]
48. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
49. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
Takahashi K; Hu B; Wang F; Yan Y; Kim E; Vitale C; Patel KP; Strati P; Gumbs C; Little L; Tippen S; Song X; Zhang J; Jain N; Thompson P; Garcia-Manero G; Kantarjian H; Estrov Z; Do KA; Keating M; Burger JA; Wierda WG; Futreal PA; Ferrajoli A
Blood; 2018 Apr; 131(16):1820-1832. PubMed ID: 29358183
[TBL] [Abstract][Full Text] [Related]
50. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
Lin K; Lane B; Carter A; Johnson GG; Onwuazor O; Oates M; Zenz T; Stilgenbauer S; Atherton M; Douglas A; Ebrahimi B; Sherrington PD; Pettitt AR
Br J Haematol; 2013 Jan; 160(1):53-62. PubMed ID: 23110309
[TBL] [Abstract][Full Text] [Related]
51. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
52. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230
[TBL] [Abstract][Full Text] [Related]
53. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young E; Noerenberg D; Mansouri L; Ljungström V; Frick M; Sutton LA; Blakemore SJ; Galan-Sousa J; Plevova K; Baliakas P; Rossi D; Clifford R; Roos-Weil D; Navrkalova V; Dörken B; Schmitt CA; Smedby KE; Juliusson G; Giacopelli B; Blachly JS; Belessi C; Panagiotidis P; Chiorazzi N; Davi F; Langerak AW; Oscier D; Schuh A; Gaidano G; Ghia P; Xu W; Fan L; Bernard OA; Nguyen-Khac F; Rassenti L; Li J; Kipps TJ; Stamatopoulos K; Pospisilova S; Zenz T; Oakes CC; Strefford JC; Rosenquist R; Damm F
Leukemia; 2017 Jul; 31(7):1547-1554. PubMed ID: 27890934
[TBL] [Abstract][Full Text] [Related]
54. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
55. Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
Morabito F; Tripepi G; Vigna E; Bossio S; D'Arrigo G; Martino EA; Storino F; Recchia AG; Fronza G; Di Raimondo F; Colombo M; Fais F; Neri A; Cutrona G; Ferrarini M; Gentile M
Eur J Haematol; 2021 Jun; 106(6):831-835. PubMed ID: 33662164
[TBL] [Abstract][Full Text] [Related]
56. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
57. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
58. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Chauzeix J; Laforêt MP; Deveza M; Crowther L; Marcellaud E; Derouault P; Lia AS; Boyer F; Bargues N; Olombel G; Jaccard A; Feuillard J; Gachard N; Rizzo D
Cancer Med; 2018 Jun; 7(6):2621-2628. PubMed ID: 29745034
[TBL] [Abstract][Full Text] [Related]
59. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.
Falisi E; Novella E; Visco C; Guercini N; Maura F; Giaretta I; Pomponi F; Nichele I; Finotto S; Montaldi A; Neri A; Rodeghiero F
Hematol Oncol; 2014 Mar; 32(1):22-30. PubMed ID: 23861036
[TBL] [Abstract][Full Text] [Related]
60. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
